{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"To assess the safety and tolerability of PCI-32765 in symptomatic WM patients with relapsed/refractory disease. Grade \\> or = 2 Adverse Events determined to be associated with PCI-32765 and subsequent outcomes will constitute the safety profile of PCI-32765 in WM. Percent of participants who experienced at least 1 grade 2 or higher treatment emergent adverse event.","groups":[{"description":"PCI-32765; ibrutinib\n\nPCI-32765: Taken orally, once daily in the morning","id":"OG000","title":"Treatment Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 years","title":"Safety and Tolerability of PCI-32765","type":"SECONDARY","unitOfMeasure":"Participants"}